Artelo Biosciences宣布：Art27.13单药减重效果媲美司美格鲁肽，联合用药减重效果翻倍——非临床肥胖模型研究揭晓

美股速递

Yesterday

Artelo Biosciences, Inc.今日发布重磅消息：其研发的Art27.13在非临床肥胖模型研究中展现出令人瞩目的减重潜力。数据显示，该候选药物作为单药疗法时，其减重效果与司美格鲁肽（Semaglutide）不相上下；更值得关注的是，当Art27.13与司美格鲁肽联合使用时，减重效果竟实现了翻倍提升。

这一突破性研究成果，为肥胖治疗领域带来了新的希望。在当前全球肥胖症日益严峻的背景下，Art27.13的优异表现无疑为患者和医疗界注入了强心剂。

Artelo Biosciences在公告中详细阐述了这一振奋人心的数据：在动物模型中，Art27.13单药治疗组的体重下降幅度与已获批准的司美格鲁肽治疗组相当；而当两种药物联合给药时，减重效果较单用司美格鲁肽翻了一番。这一发现不仅验证了Art27.13的独立疗效，更揭示了其在联合疗法中可能发挥的协同增效作用。

业内专家指出，这一结果预示着Art27.13有望成为肥胖症治疗的新选择，同时也为组合疗法的开发开辟了新的路径。Artelo Biosciences表示，公司将继续推进Art27.13的临床前研究，并计划尽快进入临床试验阶段，以进一步评估其在人类患者中的安全性和有效性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1195223082"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195223082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195223082?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-16 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195223082","market":"us","top_or_hot":-1,"title":"Artelo Biosciences宣布：Art27.13单药减重效果媲美司美格鲁肽，联合用药减重效果翻倍——非临床肥胖模型研究揭晓","media":"美股速递","content":"<p>Artelo Biosciences, Inc.今日发布重磅消息：其研发的Art27.13在非临床肥胖模型研究中展现出令人瞩目的减重潜力。数据显示，该候选药物作为单药疗法时，其减重效果与司美格鲁肽（Semaglutide）不相上下；更值得关注的是，当Art27.13与司美格鲁肽联合使用时，减重效果竟实现了翻倍提升。</p>\n<p>这一突破性研究成果，为肥胖治疗领域带来了新的希望。在当前全球肥胖症日益严峻的背景下，Art27.13的优异表现无疑为患者和医疗界注入了强心剂。</p>\n<p>Artelo Biosciences在公告中详细阐述了这一振奋人心的数据：在动物模型中，Art27.13单药治疗组的体重下降幅度与已获批准的司美格鲁肽治疗组相当；而当两种药物联合给药时，减重效果较单用司美格鲁肽翻了一番。这一发现不仅验证了Art27.13的独立疗效，更揭示了其在联合疗法中可能发挥的协同增效作用。</p>\n<p>业内专家指出，这一结果预示着Art27.13有望成为肥胖症治疗的新选择，同时也为组合疗法的开发开辟了新的路径。Artelo Biosciences表示，公司将继续推进Art27.13的临床前研究，并计划尽快进入临床试验阶段，以进一步评估其在人类患者中的安全性和有效性。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artelo Biosciences宣布：Art27.13单药减重效果媲美司美格鲁肽，联合用药减重效果翻倍——非临床肥胖模型研究揭晓</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtelo Biosciences宣布：Art27.13单药减重效果媲美司美格鲁肽，联合用药减重效果翻倍——非临床肥胖模型研究揭晓\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-09-16 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Artelo Biosciences, Inc.今日发布重磅消息：其研发的Art27.13在非临床肥胖模型研究中展现出令人瞩目的减重潜力。数据显示，该候选药物作为单药疗法时，其减重效果与司美格鲁肽（Semaglutide）不相上下；更值得关注的是，当Art27.13与司美格鲁肽联合使用时，减重效果竟实现了翻倍提升。</p>\n<p>这一突破性研究成果，为肥胖治疗领域带来了新的希望。在当前全球肥胖症日益严峻的背景下，Art27.13的优异表现无疑为患者和医疗界注入了强心剂。</p>\n<p>Artelo Biosciences在公告中详细阐述了这一振奋人心的数据：在动物模型中，Art27.13单药治疗组的体重下降幅度与已获批准的司美格鲁肽治疗组相当；而当两种药物联合给药时，减重效果较单用司美格鲁肽翻了一番。这一发现不仅验证了Art27.13的独立疗效，更揭示了其在联合疗法中可能发挥的协同增效作用。</p>\n<p>业内专家指出，这一结果预示着Art27.13有望成为肥胖症治疗的新选择，同时也为组合疗法的开发开辟了新的路径。Artelo Biosciences表示，公司将继续推进Art27.13的临床前研究，并计划尽快进入临床试验阶段，以进一步评估其在人类患者中的安全性和有效性。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARTL","symbol_name":"Artelo Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1195223082","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195223082","pubTimestamp":1789558271,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Artelo Biosciences, Inc.今日发布重磅消息：其研发的Art27.13在非临床肥胖模型研究中展现出令人瞩目的减重潜力。数据显示，该候选药物作为单药疗法时，其减重效果与司美格鲁肽不相上下；更值得关注的是，当Art27.13与司美格鲁肽联合使用时，减重效果竟实现了翻倍提升。Artelo Biosciences表示，公司将继续推进Art27.13的临床前研究，并计划尽快进入临床试验阶段，以进一步评估其在人类患者中的安全性和有效性。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ARTL":"Artelo Biosciences, Inc.","BK4007":"制药"},"translate_title":"Artelo Biosciences announced: Art27.13 single-drug weight loss effect is comparable to semaglutide, and the combination drug doubles the weight loss effect-non-clinical obesity model research revealed","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTL":1},"content_text":"Artelo Biosciences, Inc.今日发布重磅消息：其研发的Art27.13在非临床肥胖模型研究中展现出令人瞩目的减重潜力。数据显示，该候选药物作为单药疗法时，其减重效果与司美格鲁肽（Semaglutide）不相上下；更值得关注的是，当Art27.13与司美格鲁肽联合使用时，减重效果竟实现了翻倍提升。\n这一突破性研究成果，为肥胖治疗领域带来了新的希望。在当前全球肥胖症日益严峻的背景下，Art27.13的优异表现无疑为患者和医疗界注入了强心剂。\nArtelo Biosciences在公告中详细阐述了这一振奋人心的数据：在动物模型中，Art27.13单药治疗组的体重下降幅度与已获批准的司美格鲁肽治疗组相当；而当两种药物联合给药时，减重效果较单用司美格鲁肽翻了一番。这一发现不仅验证了Art27.13的独立疗效，更揭示了其在联合疗法中可能发挥的协同增效作用。\n业内专家指出，这一结果预示着Art27.13有望成为肥胖症治疗的新选择，同时也为组合疗法的开发开辟了新的路径。Artelo Biosciences表示，公司将继续推进Art27.13的临床前研究，并计划尽快进入临床试验阶段，以进一步评估其在人类患者中的安全性和有效性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}